stockrowBio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) Revenue
Bio-Rad Laboratories, Inc.'s revenue for fiscal 2025 was $2.6B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $2.6B. Over the past ten years it has ranged from $2.0B (fiscal 2015) to $2.9B (fiscal 2021); the current reading is higher than 73% of that period. Bio-Rad Laboratories, Inc. ranks 17th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.6B | 0.65% |
| FY2024 | $2.6B | (3.92%) |
| FY2023 | $2.7B | (4.67%) |
| FY2022 | $2.8B | (4.12%) |
| FY2021 | $2.9B | 14.81% |
| FY2020 | $2.5B | 10.12% |
| FY2019 | $2.3B | 0.97% |
| FY2018 | $2.3B | 5.98% |
| FY2017 | $2.2B | 4.45% |
| FY2016 | $2.1B | 2.41% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $656.4M | 0.83% |
| Jun 2026 | $651.0M | 9.95% |
| Mar 2026 | $592.1M | (14.58%) |
| Dec 2025 | $693.2M | 6.16% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $10.5B |
| BRKR Bruker Corporation compare | $3.5B |
| PODD Insulet Corporation compare | $3.2B |
| GMED Globus Medical, Inc. compare | $3.1B |
| BIO.B Bio-Rad Laboratories, Inc. | $2.6B |
| BIO Bio-Rad Laboratories, Inc. compare | $2.6B |
| PEN Penumbra, Inc. compare | $1.6B |
| GKOS Glaukos Corporation compare | $690.3M |
| TXG 10x Genomics compare | $616.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BIO.B
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement